API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Present study attests to previous report that Uttroside-B is pharmacologically safe up to five times IC50 dose in acute and sub-chronic toxicity models, while even IC50 dose of sorafenib is toxic to immunocompromised mice, and elevated doses of sorafenib adverse effects.
Lead Product(s): Uttroside B
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oklahoma Medical Research Foundation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2022
Details:
In the initial Scientific Reports study, researchers showed that in animal models, Uttroside-B was ten times more cytotoxic to the HepG2 liver cancer cell line than sorafenib, the only drug approved by the FDA for liver cancer approved at the time.
Lead Product(s): Uttroside B
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2022
Details:
The patent titled “Uttroside-B and Derivatives Thereof as Therapeutics for Hepatocellular Carcinoma” is a Method Of Use patent that covers the use of Uttroside-B for the treatment of hepatocellular carcinoma (HCC).
Lead Product(s): Uttroside B
Therapeutic Area: Oncology Product Name: Uttroside-B
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2021